PLATO Safety Results Summary No increase in overall major bleeding with BRILIQUE vs clopidogrel Non-CABG major bleeding and major + minor bleeding were more frequent with BRILIQUE vs clopidogrel No increase in overall fatal/life-threatening bleeding with BRILIQUE vs clopidogrel There are more dyspnoea-related events associated with BRILIQUE vs clopidogrel, however most events were mild to moderate in intensity and often resolved without a need for treatment BRILIQUE should be used with caution in patients at risk of bradycardic events Creatinine levels may increase during treatment with BRILIQUE; renal function should be checked after 1 month and thereafter according to routine medical practice Please reference the label for all precautions and warnings Wallentin L, et al.